Ad is loading...
ALLK
Price
$0.91
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
102 days until earnings call
HNSBF
Price
$3.65
Change
-$0.00 (-0.00%)
Updated
Oct 22 closing price
Ad is loading...

ALLK vs HNSBF

Header iconALLK vs HNSBF Comparison
Open Charts ALLK vs HNSBFBanner chart's image
Allakos
Price$0.91
Change-$0.00 (-0.00%)
Volume$453.13K
CapitalizationN/A
Hansa Medical AB
Price$3.65
Change-$0.00 (-0.00%)
Volume$200
CapitalizationN/A
ALLK vs HNSBF Comparison Chart
Loading...
ALLK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ALLK vs. HNSBF commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLK is a Hold and HNSBF is a Buy.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (ALLK: $0.91 vs. HNSBF: $3.65)
Brand notoriety: ALLK and HNSBF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLK: 43% vs. HNSBF: 115%
Market capitalization -- ALLK: $83.91M vs. HNSBF: $182.02M
ALLK [@Biotechnology] is valued at $83.91M. HNSBF’s [@Biotechnology] market capitalization is $182.02M. The market cap for tickers in the [@Biotechnology] industry ranges from $463.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLK’s FA Score shows that 1 FA rating(s) are green whileHNSBF’s FA Score has 0 green FA rating(s).

  • ALLK’s FA Score: 1 green, 4 red.
  • HNSBF’s FA Score: 0 green, 5 red.
According to our system of comparison, ALLK is a better buy in the long-term than HNSBF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLK’s TA Score shows that 5 TA indicator(s) are bullish.

  • ALLK’s TA Score: 5 bullish, 4 bearish.

Price Growth

ALLK (@Biotechnology) experienced а -23.14% price change this week, while HNSBF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was -4.97%, and the average quarterly price growth was +4.04%.

Reported Earning Dates

ALLK is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HNSBF($177M) has a higher market cap than ALLK($78.3M). HNSBF YTD gains are higher at: 61.719 vs. ALLK (-66.780). ALLK has higher annual earnings (EBITDA): -154.72M vs. HNSBF (-559.05M). HNSBF has more cash in the bank: 554M vs. ALLK (92.7M). ALLK has less debt than HNSBF: ALLK (39M) vs HNSBF (959M). HNSBF has higher revenues than ALLK: HNSBF (189M) vs ALLK (0).
ALLKHNSBFALLK / HNSBF
Capitalization78.3M177M44%
EBITDA-154.72M-559.05M28%
Gain YTD-66.78061.719-108%
P/E RatioN/AN/A-
Revenue0189M-
Total Cash92.7M554M17%
Total Debt39M959M4%
FUNDAMENTALS RATINGS
ALLK vs HNSBF: Fundamental Ratings
ALLK
HNSBF
OUTLOOK RATING
1..100
6037
VALUATION
overvalued / fair valued / undervalued
1..100
19
Undervalued
75
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
5439
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
95n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALLK's Valuation (19) in the Pharmaceuticals Major industry is somewhat better than the same rating for HNSBF (75) in the null industry. This means that ALLK’s stock grew somewhat faster than HNSBF’s over the last 12 months.

ALLK's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as HNSBF (100) in the null industry. This means that ALLK’s stock grew similarly to HNSBF’s over the last 12 months.

ALLK's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as HNSBF (100) in the null industry. This means that ALLK’s stock grew similarly to HNSBF’s over the last 12 months.

HNSBF's Price Growth Rating (39) in the null industry is in the same range as ALLK (54) in the Pharmaceuticals Major industry. This means that HNSBF’s stock grew similarly to ALLK’s over the last 12 months.

HNSBF's P/E Growth Rating (100) in the null industry is in the same range as ALLK (100) in the Pharmaceuticals Major industry. This means that HNSBF’s stock grew similarly to ALLK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLK
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 17 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
ALLK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SITE143.143.60
+2.58%
SiteOne Landscape Supply
ROG104.752.17
+2.12%
Rogers Corp
SUP2.430.04
+1.67%
Superior Industries International
NVDA146.670.78
+0.53%
NVIDIA Corp
PLSE16.12-0.02
-0.12%
Pulse Biosciences

ALLK and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLK has been loosely correlated with AXON. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLK jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLK
1D Price
Change %
ALLK100%
-3.44%
AXON - ALLK
38%
Loosely correlated
+3.52%
PRME - ALLK
38%
Loosely correlated
-0.67%
ENSC - ALLK
34%
Loosely correlated
-9.65%
AKBA - ALLK
34%
Loosely correlated
+1.68%
IMCR - ALLK
33%
Loosely correlated
-0.93%
More

HNSBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, HNSBF has been loosely correlated with ENSC. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if HNSBF jumps, then ENSC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HNSBF
1D Price
Change %
HNSBF100%
N/A
ENSC - HNSBF
33%
Loosely correlated
-9.65%
CVAC - HNSBF
33%
Poorly correlated
+2.81%
MLLCF - HNSBF
27%
Poorly correlated
N/A
LBPH - HNSBF
27%
Poorly correlated
N/A
ALLK - HNSBF
27%
Poorly correlated
-3.44%
More